OCGN
Ocugen Inc (OCGN)
Healthcare • NASDAQ • $1.39+0.72%
- Symbol
- OCGN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.39
- Daily Change
- +0.72%
- Market Cap
- $419.77M
- Trailing P/E
- N/A
- Forward P/E
- -5.28
- 52W High
- $2.73
- 52W Low
- $0.90
- Analyst Target
- $11.43
- Dividend Yield
- N/A
- Beta
- 2.21
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the tr…
Company websiteResearch OCGN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.